The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Summary

This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers. Increasing CLL patients overall physical fitness levels, through exercise during the observation stage, may provide a realistic approach means to increase survival, decrease treatment-related side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be used to strengthen the immune system of indolent NHL and CLL patients, delay time to disease progression, assess the need for treatment, and assess infection rates.

Conditions

• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Indolent Non-hodgkin Lymphoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood

OTHER

Cardiopulmonary Exercise Testing

Undergo CPET

PROCEDURE

Dual X-ray Absorptiometry

Undergo DEXA scan

OTHER

Electronic Health Record Review

Ancillary studies

OTHER

Exercise Intervention

Undergo aerobic based training program

PROCEDURE

Physical Examination

Undergo measurement of height/weight and vital signs

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Spirometry

Undergo spirometry

OTHER

Physical Performance Testing

Undergo muscular strength and functional endurance measurements

OTHER

Best Practice

Receive usual care

Sponsors & Collaborators

• Mayo Clinic

  lead OTHER

Principal Investigators

• Michael P. Gustafson, PhD · Mayo Clinic

Study Design

Allocation

NON_RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-06-12

Primary Completion

2028-03-13

Completion

2028-04-30

Countries

• United States

Study Locations